Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3872386 in healthy participants and atopic dermatitis
NCT06119529Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2023
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing Part A: LY3872386 with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events at 44 days and Serious Adverse Events at 44 days. Started Nov 2023; status: terminated.
02
Drugs
LY3872386
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06119529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06119529.